- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
B + L, CROMA donate eye drops
Bausch + Lomb and CROMA have donated 50,000 units of bromfenac sodium sesquihydrate (Yellox) to projects in Africa sponsored by Light for the World.
Vienna-Bausch + Lomb (B + L), the global eye health company, and CROMA, a private global specialty pharmaceutical and surgical company, have donated 50,000 units of bromfenac sodium sesquihydrate (Yellox), a highly effective, non-steroidal anti-inflammatory drug (NSAID) for postoperative ocular inflammation following cataract extraction, to projects in Africa sponsored by Light for the World, an Austrian organization that supports people who have no access to ophthalmic care. These eye drops are vital for post-operative treatment of cataract patients.
”It is our social responsibility and commitment to support the improvement of vision in economically challenged regions of the world," said Mag. Gerhard Prinz, CEO of CROMA Pharma GmbH. “CROMA has been contributing to Light for the World for many years and we are proud to make a difference in improving health and quality of life.”
“We are delighted to be able to support Light for the World in their effort to improve the sight of people in Africa,” said Calvin Roberts, MD, executive vice president and chief medical officer, B + L. “Proper post-operative care is the key to maximizing the surgery’s results–ultimately achieving the best possible outcome for the patient.”
For more articles in this issue of Ophthalmology Times eReport, click here.
